Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)
Clinical trial NCT03530215 · COMPLETED
Trial details
- NCT number
- NCT03530215
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2018-05-02
- Primary completion
- 2022-05-01
- Enrollment
- 500000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.